Literature DB >> 20625373

Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans.

Rebecca T Marquez1, Sarmistha Bandyopadhyay, Erik B Wendlandt, Kathy Keck, Brandon A Hoffer, Michael S Icardi, Randolph N Christensen, Warren N Schmidt, Anton P McCaffrey.   

Abstract

MicroRNAs (miRNAs) are small RNAs that regulate gene expression pathways. Previous studies have shown interactions between hepatitis C virus (HCV) and host miRNAs. We measured miR-122 and miR-21 levels in HCV-infected human liver biopsies relative to uninfected human livers and correlated these with clinical patient data. miR-122 is required for HCV replication in vitro, and miR-21 is involved in cellular proliferation and tumorigenesis. We found that miR-21 expression correlated with viral load, fibrosis and serum liver transaminase levels. miR-122 expression inversely correlated with fibrosis, liver transaminase levels and patient age. miR-21 was induced ∼twofold, and miR-122 was downregulated on infection of cultured cells with the HCV J6/JFH infectious clone, thus establishing a link to HCV. To further examine the relationship between fibrosis and the levels of miR-21 and miR-122, we measured their expression levels in a mouse carbon tetrachloride fibrosis model. As in the HCV-infected patient samples, fibrotic stage positively correlated with miR-21 and negatively correlated with miR-122 levels. Transforming growth factor β (TGF-β) is a critical mediator of fibrogenesis. We identified SMAD7 as a novel miR-21 target. SMAD7 is a negative regulator of TGF-β signaling, and its expression is induced by TGF-β. To confirm the relationship between miR-21 and the TGF-β signaling pathway, we measured the effect of miR-21 on a TGF-β-responsive reporter. We found that miR-21 enhanced TGF-β signaling, further supporting a relationship between miR-21 and fibrosis. We suggest a model in which miR-21 targeting of SMAD7 could increase TGF-β signaling, leading to increased fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625373     DOI: 10.1038/labinvest.2010.126

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  84 in total

1.  Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1.

Authors:  Chan Gyu Lee; Young Woo Kim; Eun Hyun Kim; Zhipeng Meng; Wendong Huang; Se Jin Hwang; Sang Geon Kim
Journal:  Gastroenterology       Date:  2012-01-18       Impact factor: 22.682

Review 2.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

Review 3.  Smad-mediated regulation of microRNA biosynthesis.

Authors:  Matthew T Blahna; Akiko Hata
Journal:  FEBS Lett       Date:  2012-01-28       Impact factor: 4.124

4.  miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis.

Authors:  Chuan-Feng Huang; Cheng-Chao Sun; Fang Zhao; Ya-Dong Zhang; De-Jia Li
Journal:  J Gastroenterol       Date:  2014-08-26       Impact factor: 7.527

Review 5.  MicroRNAs and liver disease.

Authors:  Thomas A Kerr; Kevin M Korenblat; Nicholas O Davidson
Journal:  Transl Res       Date:  2011-02-02       Impact factor: 7.012

Review 6.  Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation.

Authors:  Zdenko Herceg; Marie-Pierre Lambert; Karin van Veldhoven; Christiana Demetriou; Paolo Vineis; Martyn T Smith; Kurt Straif; Christopher P Wild
Journal:  Carcinogenesis       Date:  2013-06-07       Impact factor: 4.944

Review 7.  MicroRNA: master controllers of intracellular signaling pathways.

Authors:  Pak-Yin Lui; Dong-Yan Jin; Nigel J Stevenson
Journal:  Cell Mol Life Sci       Date:  2015-06-10       Impact factor: 9.261

8.  microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis.

Authors:  Timea Csak; Shashi Bala; Dora Lippai; Abishek Satishchandran; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  Liver Int       Date:  2014-07-28       Impact factor: 5.828

Review 9.  MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature.

Authors:  Paul Ravi Waldron; Mark Holodniy
Journal:  Diagn Microbiol Infect Dis       Date:  2014-06-05       Impact factor: 2.803

10.  miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Authors:  Jing Zhang; Jingjing Jiao; Silvia Cermelli; Kyle Muir; Kwang Hwa Jung; Ruhai Zou; Asif Rashid; Mihai Gagea; Sonya Zabludoff; Raghu Kalluri; Laura Beretta
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.